BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24900258)

  • 1. 3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors.
    Lindvall M; McBride C; McKenna M; Gesner TG; Yabannavar A; Wong K; Lin S; Walter A; Shafer CM
    ACS Med Chem Lett; 2011 Oct; 2(10):720-3. PubMed ID: 24900258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.
    Kurasawa O; Oguro Y; Miyazaki T; Homma M; Mori K; Iwai K; Hara H; Skene R; Hoffman I; Ohashi A; Yoshida S; Ishikawa T; Cho N
    Bioorg Med Chem; 2017 Apr; 25(7):2133-2147. PubMed ID: 28284870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
    J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
    Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
    Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors.
    Pan Y; Wang Y; Bryant SH
    J Chem Inf Model; 2013 Apr; 53(4):938-47. PubMed ID: 23496085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening.
    Chavan SR; Dash RC; Alam MS; Hirwani RR
    Mol Divers; 2014 Nov; 18(4):853-63. PubMed ID: 25112687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
    El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
    Lee YH; Yi GS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of pharmacophore and atom based 3D-QSAR model of novel isoquinolin-1-one and quinazolin-4-one-type inhibitors of TNFα.
    Hanumanthappa P; Teli MK; Krishnamurthy RG
    Med Chem; 2012 May; 8(3):436-51. PubMed ID: 22530913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
    Dev S; Dhaneshwar SR; Mathew B
    Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
    Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H
    Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
    Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M
    Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
    Jana S; Singh SK
    J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.